Development of anti-diabetic nephropathy drug targeting for transglutaminase
Project/Area Number |
26860118
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Meijo University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 終末糖化産物 / トランスグルタミナーゼ2 |
Outline of Final Research Achievements |
In the present study, we investigated the mechanism of increasing the expression of transglutaminase 2 (TG2) induced by advanced glycation endproducts (AGEs). In human renal tubular cells, we elucidated that AGEs increased the expression of TG2 via activation of NF-κb. This increasing was inhibited by inhibitor of receptor for AGEs (RAGE). These results suggested that AGEs binds to RAGE and increases the expression of TG2 via activation of NF-κb.
|
Report
(3 results)
Research Products
(2 results)